FLOVENT HFA
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Data completeness
4/8 — Partial
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOVENT HFA is a metered-dose inhaler containing fluticasone propionate, a inhaled corticosteroid used to treat asthma by reducing airway inflammation. It is a maintenance therapy delivered via inhalation that helps control asthma symptoms and prevent exacerbations. The drug works by binding to glucocorticoid receptors in the lung to suppress inflammatory cascade.
$0.395BPart D
LOE ApproachingPost-LOEProduct is in decline phase with approximately 2 years to LOE, signaling reduced commercial investment and potential team consolidation at GSK.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on FLOVENT HFA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.